Bfsg LLC Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Bfsg LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 125.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,365 shares of the company’s stock after acquiring an additional 1,315 shares during the quarter. Bfsg LLC’s holdings in Eli Lilly and Company were worth $1,379,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC raised its holdings in Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Sapient Capital LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $617,312,000. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $435,736,000. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock worth $1,778,362,000 after purchasing an additional 645,473 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on LLY. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Citigroup raised their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $13.49 during mid-day trading on Wednesday, hitting $732.20. 2,063,476 shares of the company were exchanged, compared to its average volume of 3,038,542. The company has a market capitalization of $695.71 billion, a P/E ratio of 126.78, a PEG ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12-month low of $370.68 and a 12-month high of $800.78. The business’s 50 day simple moving average is $763.89 and its two-hundred day simple moving average is $664.05.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the previous year, the company earned $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.